Lowe G D, Morrice J J, Forbes C D, Prentice C R, Fulton A J, Barbenel J C
Angiology. 1979 Sep;30(9):594-9. doi: 10.1177/000331977903000903.
Nine patients with extensive peripheral arterial disease were treated with subcutaneous injections of ancrod (Arvin) for 10 to 21 days. Reduction in plasma fibrinogen was associated with a sustained reduction in plasma and blood viscosity, and a sustained increase in nutritional skin blood flow, measured by a Xenon-133 clearance technique (P less than 0.001). These findings may be relevant to the therapeutic effect of ancrod in ischemic rest pain.
